Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Enzymatica's Board of Directors updates the financial targets

The Board of Directors of Enzymatica AB (publ) has decided to update the company's financial goals. The background is that the company will likely develop the company's business model, so that in addition to being a producer of consumer products, Enzymatica will also become a supplier of enzyme formulations. The new business model is estimated to yield a higher EBIT margin, but lower net sales compared to the calculations that were the basis for the previous financial targets. In November 2021, Enzymatica's board decided that the company's financial goal would be a net turnover of at

Employee Long Term Incentive Plan and Issue of Equity

18 July 2024   [A close-up of a logo Description automatically generated]          4basebio PLC ("4basebio" or the "Company")   Employee Long Term Incentive Plan and Issue of Equity   Cambridge, UK, 18 July 2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that it has awarded 5,520 ordinary shares of EUR€1.00 each in the Company (“EBT Shares”) to the Employees Benefit Trust (“EBT”), operated by Fiduchi Trustees (UK) Limited at £15.60 per

Notice of Extraordinary General Meeting in Enzymatica AB (publ)

The shareholders in Enzymatica AB (publ), reg. no 556719-9244 (the "Company") are hereby invited to attend the Extraordinary General Meeting ("EGM") to be held on August 6, 2024 at 13:00 CET at Ideon Science Park, Scheelevägen 19 in Lund. Notification etc. Those who wish to participate in the annual general meeting must:   i. be listed as a shareholder in the presentation of the share register prepared by Euroclear Sweden AB concerning the circumstances as per the record date of July 29, 2024; andii. give notice of intent to participate no later than July 31, 2024.

Janet Street-Porter reveals what Norwich and Norfolk people most like to read about

Embargoed: 16.00 hours 17 July 2024 Take That playing at Carrow Road,  Norwich Airport extending its flights to Malta, Alicante and Faro and Anglia Square Shopping Centre going up for sale are the top stories people in Norwich and Norfolk have enjoyed reading about so far this year according to research by Readly , the digital magazine and newspaper app. Other top moments involved the first East Anglian football derby between Norwich City and Ipswich Town since 2019 (24%) and Steve Coogan - otherwise known as Alan Partridge - spotted smelling cheeses

Neste to publish its half-year results on 25 July 2024

Neste Corporation, Press Release, 18 July 2024 at 9 a.m. (EET)Neste will publish its half-year 2024 results on Thursday, 25 July 2024 at approximately 9 a.m. (EET). The release will be available on the Neste website  immediately after publishing.A conference call in English for investors and analysts will be held on 25 July 2024, at 3 p.m. Finland / 1 p.m. London / 8 a.m. New York. In order to receive the participant dial in numbers and a unique personal PIN, participants are requested to register using this link: https://register.vevent.com/register/

ContextVision enters Data Quality market with organ-specific enhancements

Stockholm, Sweden, July 18, 2024 – ContextVision, a leading provider of medical image processing and analysis technology, is excited to announce a strategic evolution of its Image Quality business. In response to the rapidly advancing digital transformation in healthcare, ContextVision is expanding its product pipeline into Data Quality, preparing to establish vital clinical and commercial partnerships.Expanding product pipeline from Image Quality to Data Quality ContextVision is committed to expanding its Image Quality business, which today focuses on enhancing medical image quality for

Transaction in Own Shares

    18 July 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |17/07/2024|+--------------------------------------------------------------

Inside information: Fortum to sell its recycling and waste business to Summa Equity for approximately EUR 800 million

FORTUM CORPORATION INSIDE INFORMATION 18 JULY 2024 AT 9:00 EEST Fortum has today signed an agreement to sell its recycling and waste business to the thematic impact investment firm, Summa Equity through its portfolio company NG Group. The total consideration on a debt- and cash-free basis is approximately EUR 800 million. Based on the balance sheet available at signing, Fortum would record a tax-exempt capital gain of approximately EUR 110 million, however, the final capital gain will depend on the balance sheet value at closing. The gain will be reported as Items Affecting Comparability

REPORT ON THE SECOND QUARTER 2024

INCREASED MARGIN, STRONG OPERATING CASH FLOW AND IMPROVED LEVERAGE SECOND QUARTER 2024 · Net sales were SEK 7,662 m (8,329); a decrease of -8%, of which -8% was organic growth. · Operating profit (EBITA) before items affecting comparability) was SEK 1,069 m (1,177), corresponding to a margin of 14.0% (14.1%). Excluding a previously disclosed one-time positive effect of SEK 33 m in the second quarter 2023, the margin for the second quarter 2023 was 13.7%. · Operating profit (EBIT) was SEK 903 m (985), corresponding to a margin of 11.8% (11.8%). · Profit for the quarter was

Midsona Interim Report January-June 2024

Organic growth and significant improvement in operating profit during the quarter  April–June 2024 (second quarter)· Net sales amounted to SEK 918 million (893), corresponding to growth of 2.8 percent (–6.6). The organic change in net sales was 2.7 percent (–11.0). · Gross profit amounted to SEK 265 million (222), corresponding to a margin of 28.9 percent (24.9), and gross profit, before items affecting comparability, amounted to SEK 265 million (236), corresponding to a margin of 28.9 percent (26.4). · Operating profit/loss amounted to SEK 22 million (–15), corresponding to a

Hemnet Group Interim report Q2 2024

Summary for the period April-June 2024 · Net sales increased by 51.3 percent to SEK 405.0m (267.6) · EBITDA increased 53.7 percent to SEK 216.2m (140.7) · Operating profit increased 60.7 percent to SEK 195.6m (121.7) · ARPL, average revenue per listing, increased 51.6 percent to SEK 6,274 (4,138) Summary for the period January-June 2024 · Net sales increased by 43.8 percent to SEK 658.4m (457.7) · EBITDA increased 47.4 percent to SEK 335.9m (227.9) · Operating profit increased 55.2 percent to SEK 294.5m (189.8) · ARPL, average revenue per published listing,

NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A

· XTEND-Kids is the first assessment of once-weekly ALTUVOCT® prophylaxis in previously treated children · Results indicate highly effective bleed protection in children under 12 years of age with severe haemophilia A Sobi® today announced the publication of full results from the Phase 3 XTEND-Kids study in The New England Journal of Medicine (NEJM) confirming the safety and efficacy profile of ALTUVOCT® (efanesoctocog alfa), in children younger than 12 years old with severe haemophilia A. The study demonstrated that fixed-dose once-weekly prophylaxis with ALTUVOCT, a new class of

Implantica launches RefluxStop™ advanced education program in Spain

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, brings together top anti-reflux surgeons in Spain to create a community of excellence to share RefluxStop™ data, insights, and the best practices, driving advancements in the surgical treatment field of gastroesophageal reflux disease (GERD).During June and July 2024, more than 15 anti-reflux surgeons and gastroenterologists from seven leading reflux hospitals across Spain participated in RefluxStop™ advanced education events covering the latest clinical outcomes data, surgical

Getinge Interim Report April-June 2024: Higher sales, stronger margins and product launches with significant added value for customers

“Net sales increased by 15.7% in the second quarter, of which the organic increase was 8.9%,” says Mattias Perjos, President & CEO at Getinge. “The operating margin improved compared with last year due to strong sales and a positive product mix, which supports a solid financial position that enables investments in profitable growth.”Getinge’s order intake increased by 14.4%, of which organic growth was 7.8% due to positive performance in all business areas. Investments in the product portfolio is a fundamental piece of the medtech company’s strategy and during the quarter numerous important

Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, BELARUS, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR INVOLVE REQUIREMENTS FOR MEASURES OTHER THAN WHAT FOLLOWS BY SWEDISH LAW. The board of Enzymatica AB (publ) ("Enzymatica" or the "Company") has decided to carry out a rights issue of approximately SEK 130 million with preferential rights for existing shareholders (the “Rights issue”). The Rights issue is

Interim report 2024, January 1 – June 30

The second quarter saw continued robust revenue growth and improved profit. Organic growth remains burdened by challenging comparables from 2023 driven by very strong sales in pharmaceuticals and rental of equipment for clinical trials, but with organic order intake well back in positive territory with several large new orders, we are optimistic about the second half of the year. April – June 2024 Net revenue for the period was SEK 412.3 million (344.4), an increase of 19.7% On an organic basis, net revenue declined by 20.6% Orders received for the period was SEK 534.0 million (

Lagercrantz Interim Report Q1 2024/25

first quarter (1 April – 30 June 2024) · Net revenue increased by 10% to MSEK 2,253 (2,045). · Operating profit (EBITA) increased by 8% to MSEK 386 (357), where the EBITA margin was 17.1% (17.5). · Profit after financial items (EBT) increased by 9% to MSEK 302 (277). · Cash flow from operating activities amounted to MSEK 235 (286). · Profit after taxes increased by 6% to MSEK 222 (209). · Return on equity amounted to 26% (28) and the equity ratio was 36% (38). · Earnings per share for the latest 12-month period increased to SEK 4.32 (SEK 4.25 for the 2023/24 financial

SRV Half-year Report 1–6/2024: Operative operating profit increased driven by strong growth in revenue, the order backlog remains strong

SRV GROUP PLC     HALF-YEAR FINANCIAL REPORT      18 JULY 2024    AT 08.30 EESTSRV Half-year Report 1–6/2024: Operative operating profit increased driven by strong growth in revenue, the order backlog remains strong  April–June 2024 in brief: · Revenue amounted to EUR 186.3 (143.1) million (+30.2%). Revenue increased especially in alliance and project management contracts in business construction. Revenue from housing construction declined. · Operative operating profit amounted to EUR 1.5 (-3.9) million with an operating profit of EUR 1.5 (-3.0) million. Operative operating

Oriola Corporation’s Half-Year Report January-June 2024

Oriola Corporation Stock Exchange Release 18 July 2024 at 8.30 a.m. EEST Oriola Corporation’s Half-Year Report January-June 2024 Continued sales growth in both segments April-June 2024 highlights · Invoicing increased by 5.3 % to EUR 952.2 (904.3). On a constant currency basis, invoicing increased by 5.5% and was EUR 954.4 million. · Net sales increased by 13.0% to EUR 439.4 (389.0) million. On a constant currency basis, net sales increased by 13.3% and were EUR 440.6 million. · Adjusted EBIT was EUR 5.1 (3.4) million. On a constant currency basis, the adjusted EBIT was

Q2 2024 interim report January-June

Continued focus on operational improvements and product performance   Second quarter highlights >         Total reported Group net sales of SEK 4,485m (4,591) and total operating income before associated company income (ACI) and items affecting comparability (IAC) of SEK -70m (-273) >         2.6% organic sales growth for core operations (Nordics, Netherlands and Viaplay Select), with sales of SEK 4,292m (4,282) and operating income before ACI and IAC of SEK -72m (82) >         Total reported operating income of SEK 7m (-6,551) including ACI of SEK 28m (2) and IAC1 of SEK 48m

Fiskars Corporation Half-year Financial Report for January-June 2024

Fiskars CorporationHalf-year financial reportJuly 18, 2024 at 8:30 a.m. (EEST) Fiskars Corporation Half-year Financial Report for January-June 2024 Another solid quarter in challenging market conditions – accelerating efficiency improvements This release is a summary of the Fiskars Corporation’s Half-year Financial Report for January-June 2024 published today. The complete Half-year Financial Report with tables is attached to this release as a pdf-file. It is also available at https://fiskarsgroup.com/investors/reports-and-presentations/annual-and-interim-reports/ and on the

Dynavox Group Interim Report second quarter 2024

Dynavox Group AB (publ) today announced its results for the second quarter 2024. Comment from the Dynavox Group CEO Fredrik Ruben: We continue to grow sales at a rapid pace while investing in back-end systems and sales capacity to improve the scalability of the business. This is in line with our long-term goal of helping more people, combined with high growth and a stronger operating margin. The limited awareness of assistive communication continues to offer significant potential for us to achieve long-term growth and make a difference for many more individuals with communication

There are no items matching the current filter
There are no more items matching the current filter
Back to top